GT
NVS icon

Greenleaf Trust’s Novartis NVS Stock Holding History

Greenleaf Trust’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Sell
14,361
-121
-0.8% -$18.1K 0.02% 200
2026
Q1 		$2.21M Buy
14,482
+58
+0.4% +$8.89K 0.02% 186
2025
Q4 		$1.99M Buy
14,424
+728
+5% +$95.3K 0.02% 202
2025
Q3 		$1.76M Buy
13,696
+382
+3% +$46.6K 0.02% 226
2025
Q2 		$1.61M Sell
13,314
-4,310
-24% -$486K 0.01% 234
2025
Q1 		$1.96M Sell
17,624
-169
-0.9% -$18K 0.02% 200
2024
Q4 		$1.73M Buy
17,793
+192
+1% +$20.5K 0.02% 219
2024
Q3 		$2.02M Buy
17,601
+1,445
+9% +$164K 0.02% 202
2024
Q2 		$1.72M Sell
16,156
-1,211
-7% -$122K 0.02% 202
2024
Q1 		$1.68M Sell
17,367
-278
-2% -$28.5K 0.02% 211
2023
Q4 		$1.78M Sell
17,645
-19
-0.1% -$1.83K 0.02% 194
2023
Q3 		$1.8M Buy
17,664
+1,455
+9% +$148K 0.02% 173
2023
Q2 		$1.64M Buy
16,209
+532
+3% +$53.2K 0.02% 196
2023
Q1 		$1.44M Sell
15,677
-288
-2% -$25.2K 0.02% 212
2022
Q4 		$1.45M Sell
15,965
-87
-0.5% -$7.33K 0.02% 201
2022
Q3 		$1.22M Buy
16,052
+681
+4% +$56.5K 0.02% 206
2022
Q2 		$1.3M Buy
15,371
+883
+6% +$77.5K 0.02% 189
2022
Q1 		$1.27M Sell
14,488
-867
-6% -$75.1K 0.02% 201
2021
Q4 		$1.34M Sell
15,355
-5,832
-28% -$484K 0.02% 189
2021
Q3 		$1.73M Sell
21,187
-303
-1% -$27.3K 0.02% 144
2021
Q2 		$1.96M Sell
21,490
-1,182
-5% -$105K 0.02% 129
2021
Q1 		$1.94M Buy
22,672
+2,254
+11% +$202K 0.03% 120
2020
Q4 		$1.93M Buy
20,418
+79
+0.4% +$6.9K 0.03% 111
2020
Q3 		$1.77M Buy
20,339
+348
+2% +$30.1K 0.03% 111
2020
Q2 		$1.75M Sell
19,991
-5,386
-21% -$465K 0.03% 105
2020
Q1 		$2.09M Buy
25,377
+863
+4% +$77K 0.04% 87
2019
Q4 		$2.32M Sell
24,514
-1,420
-5% -$127K 0.04% 92
2019
Q3 		$2.25M Buy
25,934
+363
+1% +$32.6K 0.04% 96
2019
Q2 		$2.33M Sell
25,571
-2,708
-10% -$229K 0.04% 91
2019
Q1 		$2.44M Sell
28,279
-3,202
-10% -$257K 0.04% 84
2018
Q4 		$2.42M Buy
31,481
+9,463
+43% +$737K 0.05% 83
2018
Q3 		$1.7M Buy
22,018
+10,006
+83% +$740K 0.03% 110
2018
Q2 		$813K Sell
12,012
-2,729
-19% -$188K 0.02% 188
2018
Q1 		$1.07M Buy
14,741
+1,511
+11% +$115K 0.02% 142
2017
Q4 		$995K Sell
13,230
-3,065
-19% -$231K 0.02% 153
2017
Q3 		$1.25M Buy
16,295
+3,859
+31% +$291K 0.03% 133
2017
Q2 		$930K Buy
12,436
+1,102
+10% +$78.1K 0.02% 137
2017
Q1 		$754K Buy
11,334
+7,068
+166% +$471K 0.02% 125
2016
Q4 		$278K Sell
4,266
-492
-10% -$31.9K 0.01% 186
2016
Q3 		$337K Buy
+4,758
New +$347K 0.01% 149
2016
Q1 		– Sell
-2,803
Closed -$216K – 173
2015
Q4 		$216K Hold
2,803
– – 0.01% 159
2015
Q3 		$231K Sell
2,803
-42
-1% -$3.74K 0.01% 163
2015
Q2 		$251K Sell
2,845
-33
-1% -$3.03K 0.01% 142
2015
Q1 		$254K Sell
2,878
-974
-25% -$86.4K 0.01% 132
2014
Q4 		$320K Sell
3,852
-1,054
-21% -$87.4K 0.01% 128
2014
Q3 		$414K Buy
4,906
+1,677
+52% +$136K 0.01% 111
2014
Q2 		$262K Sell
3,229
-30
-0.9% -$2.36K 0.01% 134
2014
Q1 		$248K Sell
3,259
-13,942
-81% -$1.02M 0.01% 139
2013
Q4 		$1.24M Sell
17,201
-3,986
-19% -$277K 0.04% 70
2013
Q3 		$1.46M Sell
21,187
-246
-1% -$16.3K 0.05% 58
2013
Q2 		$1.36M Buy
+21,433
New +$1.39M 0.05% 60

Other funds holding NVS

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SI
Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Greenleaf Trust's NVS Position: Q2 2026 in Review

Greenleaf Trust reduced its Novartis (NVS) stake by 0.84% in Q2 2026, selling an estimated $18.1K and leaving 14,361 shares worth $2.25M. The position accounts for 0.02% of the portfolio, ranked #200.

Greenleaf Trust first reported a position in NVS in Q2 2013 and has held it in 51 quarters since. The position peaked at $2.44M in Q1 2019. 652 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Greenleaf Trust held 14,361 shares of Novartis worth $2.25M as of Q2 2026.
  • Greenleaf Trust sold 121 Novartis shares in Q2 2026, an estimated $18.1K.
  • Novartis made up 0.02% of Greenleaf Trust's portfolio in Q2 2026, its #200 holding.
  • Greenleaf Trust first reported a position in Novartis in Q2 2013 and has held it in 51 quarters since.
  • Greenleaf Trust's Novartis position peaked at $2.44M in Q1 2019.
  • 652 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.